Market Overview
The global glycomics market was valued at USD 1.7 Billion in 2024 and is forecasted to reach USD 4.5 Billion by 2033, growing at a CAGR of 10.61% during 2025-2033. Growth is driven by the rising incidence of chronic diseases, advancements in biotechnology, and increasing investments in glycoengineering and drug development. North America dominates the market with over 39.1% share due to robust research infrastructure and pharmaceutical sector investments.
Study Assumption Years
• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033
Glycomics Market Key Takeaways
• The glycomics market size was USD 1.7 Billion in 2024.
• The market is expected to exhibit a CAGR of 10.61% from 2025 to 2033.
• North America dominates with a 39.1% market share in 2024.
• The rising incidence of chronic diseases and increasing focus on glycoengineering techniques are key growth drivers.
• An increasing number of contract research organizations involved in drug and biologics development is fueling the market.
• Technological advancements such as high-throughput glycan profiling and enhanced mass spectrometry are accelerating research.
• Government and private funding for glycobiology research is expanding globally.
Sample Request Link:
https://www.imarcgroup.com/Glycomics-Market/requestsample
Market Growth Factors
The global glycomics market is expected to grow because of the rise of chronic diseases worldwide which should create more need for glycan-based tools for diagnosis and treatment. Also, pharmaceutical and biotechnology companies researching and developing glycan-based drugs and personalized medicine are expected to drive this market during the forecast period. Another innovation imported from the medical field is that of biologics such as monoclonal antibodies and glycoprotein therapies, making glycan analysis critical.
There are growing capabilities for glycomics research due to increased efficiency in protocols (such as high-throughput glycan profiling or more powerful mass spectrometry technologies). Government and private funding of glycobiology research is increasing, and collaboration among academia, industry, and research institutions is allowing growth in both the rate of innovation and the products and technologies originating from glycomics research.
Personalized medicine is increasing in importance, such as exemplified by the United States Precision Medicine Initiative, with growing budgets from the National Institutes of Health. Glycans may play important roles in diagnostics, prognosis and treatment across a wide variety of human diseases. The incorporation of emerging glycomics profiling technologies, such as glycan microarrays and glycan sequencing, for identification of disease-specific glycan signatures is driving the market.
Market Segmentation
By Product
• Enzymes: Represent 29.6% market share. Enzymes such as glycosidases, glycosyltransferases, and glycosyl hydrolases are vital for glycan release, structural analysis, and modification, facilitating comprehensive glycomics analysis.
• Instruments: Include mass spectrometers, HPLC, MALDI-TOF, and array systems critical for precise glycan profiling and analysis.
• Kits: Comprise glycan labeling, purification, and release kits, supporting various glycomics workflows.
• Reagents: Include glycoproteins, monosaccharides, and oligosaccharides used in glycomics research.
By Application
• Drug Discovery and Development: Holds the largest market share at 43.6%, providing crucial insight into glycans roles in disease mechanisms, drug efficacy, and safety, enabling glycan-based therapies and improved drug screening.
• Diagnostics: Focuses on glycan-based biomarkers for disease detection.
• Others: Include other applications related to glycomics research.
By End User
• Academic and Research Institutes: Command 38.7% market share, leading glycomics research supported by advanced laboratories and interdisciplinary collaboration.
• Pharmaceutical and Biotechnology Companies: Use glycomics for drug development and personalized medicine.
• Contract Research Organizations: Engage in glycomics for contract-based research services.
Regional Insights
North America leads the glycomics market with a 39.1% share in 2024, attributed to renowned academic institutions, robust research infrastructure, and significant investments in pharmaceutical and biotechnology sectors. The region benefits from favorable regulations, strong intellectual property protections, and advanced healthcare facilities fostering glycomics innovation and commercialization.
Recent Developments & News
• December 2024: GlycoNet partnered with Michael Smith Health Research BC to study complex sugars for health issues, supported by USD 12 million funding.
• March 2024: Bruker Corporation announced progress in immunopeptidomics and glycoproteomics, enhancing disease biomarker research.
• February 2024: GlycanAge raised USD 4.2 million in seed funding to advance glycan biomarker-based personalized healthcare.
• January 2024: Navinci Diagnostics and Vector Laboratories collaborated on biomarker discovery using glycomic research for molecular diagnostics.
Key Players
• Agilent Technologies Inc.
• Asparia Glycomics
• Bruker Corporation
• Danaher Corporation
• Dextra Laboratories Limited
• Merck KGaA
• New England Biolabs
• RayBiotech Life Inc.
• Shimadzu Corporation
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• Waters Corporation
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Request For Customization: https://www.imarcgroup.com/request?type=report&id=5689&flag=E
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302
